Botulinum toxin-induced focal paresis in mice is unaffected by muscle activity

Muscle and Nerve

Volumn 44, Issue 6, 2011, Pages 930-936

  Kutschenko, Anna ^a   Reinert, Marie Christine ^a   Klinker, Florian ^a   Paulus, Walter ^a   Hesse, Stefan ^b   Liebetanz, David ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Botulinum toxin; Focal paresis; Mice; Muscle activity; Wheel running

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALF (BOVINE); IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; MUSCLE CONTRACTION; NEUROMUSCULAR SYNAPSE; NONHUMAN; PARESIS; PRIORITY JOURNAL;

ANIMALS; BOTULINUM TOXINS; EXERCISE TEST; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; NEUROMUSCULAR JUNCTION; PARESIS; RANDOM ALLOCATION; RUNNING;

EID: 81555208493     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22210     Document Type: Article

References (30)

1. Hallett M, Glocker FX, Deuschl G. Mechanism of action of botulinum toxin. Ann Neurol 1994;36:449-450.
2. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Phil Trans R Soc Lond B Biol Sci 1999;354:259-268.
3. Schantz EF, Johnson EA. Dose standardization of botulinum toxin. Lancet 1990;335:421.
4. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-247.
5. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237-254.
6. Jankovic J, Schwarth K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53:633-639.
7. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45:712-717.
8. Hesse S, Brandi-Hesse B, Bardeleben A, Werner C, Funk M. Botulinum toxin A treatment of adult upper and lower limb spasticity. Drugs Aging 2001;18:255-262.
9. Glocker FX, Guschlbauer B, Lücking CH, Deuschl G. Effects of local injections of botulinum toxin on electrophysiological parameters in patients with hemifacial spasm: role of synaptic activity and size of motor units. Neurosci Lett 1995;187:161-164.
10. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995;201:37-40.
11. Chen R, Karp BI, Goldstein SR, Bara-Jimenez W, Yaseen Z, Hallett M. Effect of muscle activity immediately after botulinum toxin injection for writer's cramp. Mov Disord 1999;14:307-312.
12. Hughes R, Whaler BD. Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin. J Physiol 1962;160:221-233.
13. Simpson LL. Kinetic studies of the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-21.
14. Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord 1997;12:89-94.
15. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebocontrolled trial. Clin Rehabil 1998;12:381-388.
16. Kim HS, Hwang JH, Jeong YT, Lee PK, Suh YL, Shim JS. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003;45:200-206.
17. Frasson E, Priori A, Ruzzante B, Didone G, Berolasi L. Nerve stimulation boosts botulinum toxin action in spasticity. Mov Disord 2005;20: 624-629.
18. Liebetanz D, Merkler D. Effects of commissural de-and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis. Exp Neurol 2006;202:217-224.
19. Liebetanz D, Baier PC, Paulus W, Meuer K, Bähr M, Weishaupt JH. A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease. Exp Neurol 2007;205:207-213.
20. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 1997;147:96-102.
21. Dressler D, Lange M, Bigalke H. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B. Mov Disord 2005; 20:1617-1619.
22. Cull-Candy SG, Lundh H, Thesleff S. Effects of botulinum toxin on neuromuscular transmission in the rat. J Physiol 1976;260:177-203.
23. Sellin LC, Kauffman JA, Dasgupta BR. Comparison of the effects of botulinum neurotoxin types A and E at the rat neuromuscular junction. Med Biol 1983;61:120-125.
24. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001;39:1815-1820.
25. Jurasinski CV, Lieth E, Dang Do AN, Schengrund CL. Correlation of cleavage of SNAP-25 with muscle function in a rat model of botulinum neurotoxin type A induced paralysis. Toxicon 2001;39:1309-1315.
26. Keller KE. Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 2006;139:629-637.
27. Park ES, Rha DW, Lee JD, Yoo JK, Chang WH. The short-term effects of combined modified constraint-induced movement therapy and botulinum toxin injection for children with spastic hemiplegic cerebral palsy. Neuropediatrics 2009;40:269-274.
28. Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007;21:331-337.
29. Albany K. Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity. Muscle Nerve 1997;6(suppl):S221-S231.
30. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 1986;103:535-544.